The association between physical activity and human disease has not been examined using commercial devices linked to electronic health records. Using the electronic health records data from the All of Us Research Program, we show that step count volumes as captured by participants’ own Fitbit devices were associated with risk of chronic disease across the entire human phenome. Of the 6,042 participants included in the study, 73% were female, 84% were white and 71% had a college degree, and participants had a median age of 56.7 (interquartile range 41.5–67.6) years and body mass index of 28.1 (24.3–32.9) kg m⁻². Participants walked a median of 7,731.3 (5,866.8–9,826.8) steps per day over the median activity monitoring period of 4.0 (2.2–5.6) years with a total of 5.9 million person-days of monitoring. The relationship between steps per day and incident disease was inverse and linear for obesity (n = 368), sleep apnea (n = 348), gastroesophageal reflux disease (n = 432) and major depressive disorder (n = 467), with values above 8,200 daily steps associated with protection from incident disease. The relationships with incident diabetes (n = 156) and hypertension (n = 482) were nonlinear with no further risk reduction above 8,000–9,000 steps. Although validation in a more diverse sample is needed, these findings provide a real-world evidence-base for clinical guidance regarding activity levels that are necessary to reduce disease risk.
period (most often 7 days)\(^1\)\(^-\)\(^4\). As a result, activity may be under- or over-reported. Moreover, no information is reported about activity levels between the baseline period and when outcomes are assessed at follow-up, often many years later. Second, prior studies have focused on a relatively targeted set of outcomes limited to mortality, diabetes, and cardiovascular disease. Little is known about the impact of activity over time on developing chronic diseases across the full human phenome, which represents the sum of human traits and conditions resulting from genetic and behavioral variation in a population.\(^7\)

The All of Us Research Program (AoURP) is an initiative that is accumulating multiple streams of health-related information (for example, electronic health records (EHRs), genomics, physical measures, participant surveys and wearables such as Fitbit) in 1,000,000 or more Americans and includes a focus on populations usually under-represented in biomedical research to date.\(^7\) The rich EHR data within AoURP can be used to identify the incidence of chronic conditions across the human phenome.\(^7\) Thus, the AoURP dataset provides a unique opportunity to directly examine the effects of physical activity over time on health outcomes using wearables and clinical data.

The purpose of this study was to examine the associations between physical activity over time and incident chronic diseases. Based on previous literature, we hypothesized that more steps per day over time will be associated with lower incidence of chronic diseases. We also sought to identify empiric, evidence-based activity levels associated with risk of, and protection from, chronic disease, which could inform public health guidance on physical activity.

Results

Participant characteristics

Of the 329,070 AoURP participants at the time of our analysis, 214,206 participants had consented to share EHR data. Of those sharing EHR data, 6,042 participants linked their own Fitbit device, had valid Fitbit data over at least 6 months of total monitoring and were aged at least 18 years at any time during the monitoring period (Extended Data Fig. 1). Only 0.2% and 0.4% of total days were excluded given they had fewer than 100 steps and <6 months of monitoring, respectively. Participants had a median age of 56.7 years (interquartile range (IQR) 41.5–67.6) and median body mass index (BMI) of 28.1 kg m\(^{-2}\) (IQR 24.3–32.9) at baseline (Table 1). Nearly 73%, 84% and 71% were female, white and with a college degree, respectively. The median daily step counts were 7,731 (IQR 5,867–9,827) steps per day over Fitbit monitoring duration of 4.0 years (IQR2.2–5.6), representing 5,991,662 person-days of monitoring and nearly 50.6 billion total steps. Participants with Fitbit and EHR data were more likely to be white, female and to have a lower burden of medical comorbidities compared with those sharing EHR data alone (Table 1).

Daily steps and chronic diseases across human phenome

Our first analysis involved exploratory examination of the relationship between average step counts over an individual’s entire monitoring period and incident disease across all 1,711 phenomes. Figure 1a,b shows these data in a logistic regression model adjusted for age, sex and race set to an effect size (odds ratio (OR)) per 1,000 step increase. ORs <1 indicate that higher step counts were associated with lower risk of each condition. Incident chronic conditions with the largest effect sizes that met the adjusted statistical significance threshold across the human phenome after a minimum of 6 months of monitoring were obstructive sleep apnea \((n=342/5,518, OR (95% confidence intervals (CI)) = 0.88 (0.84, 0.92)), obesity \((n=380/5,267, OR (95% CI) = 0.89 (0.86, 0.93)), type 2 diabetes with neurological manifestations \((n=37/5,976, OR (95% CI) = 0.69 (0.60, 0.79)), hypertension \((n=498/4,897, OR (95% CI) = 0.92 (0.89, 0.95)), gastroesophageal reflux disease (GERD) \((n=451/5,091, OR (95% CI)= 0.92 (0.89, 0.95)\) and major depressive disorder (MDD) \((n=483/5,370, OR (95% CI) = 0.92 (0.89, 0.95))\) (Fig. 1 and Supplementary Table 2).

We focused subsequent analyses on chronic conditions with a plausible biological link to activity levels including diabetes, hypertension, GERD, MDD, obesity and sleep apnea (Supplementary Table 1). Type 2 diabetes codes with neurological manifestation were combined with codes for type 2 diabetes, and sleep apnea and obstructive sleep apnea were combined into a single condition given their phenotypic and diagnostic overlap. The conditions that were of interest in time

| Variable | Included | Excluded | P value |
|----------|----------|----------|---------|
| Subjects (n) | 6,042 | 208,164 | 0.373 |
| Age | 56.69 (41.45–67.62) | 56.91 (40.96–68.24) | <0.001 |
| Race | <0.001 | <0.001 | <0.001 |
| Ethnicity | <0.001 | <0.001 | <0.001 |
| Education | <0.001 | <0.001 | <0.001 |
| No college | 356 (5.9) | 66,925 (32.2) | <0.001 |
| BMI | 28.10 (24.32–32.85) | 28.80 (24.70–34.10) | <0.001 |
| Baseline conditions | <0.001 | <0.001 | <0.001 |
| CAD | 170 (2.8) | 14,684 (73.1) | <0.001 |
| Cancer | 1,429 (23.7) | 58,050 (279) | <0.001 |
| Smoking (100 cigarettes) | >100 cigarettes | 1,932 (32.0) | 84,466 (40.6) | <0.001 |
| Alcohol | 5,846 (96.8) | 177,735 (85.4) | <0.001 |
| Fitbit variables | 7,731.30 (5,866.84–9,826.85) | <0.001 | <0.001 |

Data are median (IQR) for continuous variables and frequency (percentage) for categorical variables. Participants were excluded because of not having EHR and Fitbit data or valid Fitbit data for at least 6 months. For included participants, missingness for each variable was as follows: Race, 325 (5.4%); Sex, 84 (1.4%); Ethnicity, 76 (1.3%); BMI, 5,644 (43.8%); Smoking, 108 (1.8%); Education, 23 (0.4%); Alcohol, 31 (0.5%). For excluded participants, missingness for each variable was as follows: Race, 43,250 (21.9%); Sex, 4,036 (1.4%); Ethnicity, 6,158 (3.0%); BMI, 5,496 (24.7%); Smoking, 6,094 (2.9%); Education, 4,859 (2.3%); Alcohol, 6,477 (3.1%). For included participants, BMI had a high amount of missingness because the measurement must have occurred before the Fitbit monitoring period. Mann–Whitney U and chi-squared tests for continuous and categorical variables, respectively, were used to compare these clinical characteristics for the participants who were excluded versus included in the analytical dataset for this study.
to event analyses often coexist clinically, but multimorbidity among these six conditions was rare in this cohort (Extended Data Fig. 2). In addition to removing conditions that did not meet the statistical significance threshold in logistic regression, acute conditions (acute renal failure), nonspecific diagnoses (nausea and vomiting, shortness of breath, urinary incontinence, dysphagia, complications of transplants, inflammatory and toxic neuropathy), those with few events, that is, \( n \leq 50 \) (convulsions, heart failure with preserved ejection fraction) and those with little to no plausible link to activity (hypopotassemia) were not pursued in subsequent analyses.

**Time-varying analysis of daily step counts and disease risk**  
In the Cox models, 15.4–16.0% of months (that is, 4.7–4.9% of days) were excluded due to fewer than 15 valid days of data. Figure 2a shows the relationship between step counts and adjusted hazard ratio (HR) for an incident diagnosis of each condition referenced to the median daily average steps for the entire cohort. The median values ranged from 8,160 to 8,290 steps per day across the different analytical cohorts created to investigate each incident diagnosis.

The relationship between steps and incident disease was inverse (all \( P < 0.001 \)) and linear for obesity, sleep apnea, GERD and MDD (chunk tests for nonlinearity were nonsignificant for those conditions) with a lower risk of each diagnosis at higher step counts. For example, in comparison with the median step count, the risk of obesity declined by 31% (HR 0.69, 95% CI 0.53, 0.88) when steps were increased to 10,000 per day. In contrast, incident diabetes and hypertension had a nonlinear relationship (chunk tests for nonlinearity \( P < 0.05 \) for both) with step counts demonstrating inflection points at approximately 9,000 and 8,000 steps, respectively, where risk plateaued at higher step counts. Figure 2b shows the estimated cumulative rates of a new diagnosis for 3, 5 and 7 years, which shows how risk changes when an average step count is maintained over time. In general, incident risk for all the years is higher at lower step counts and increases over time when a given step count is maintained. For example, the risk of new hypertension diagnosis at 6,000 steps per day is maintained at 4%, 10% and 17% at 3, 5 and 7 years, respectively. Risk for all conditions except hypertension asymptotically approached zero at very high daily step counts. Extended Data Fig. 3a shows the HR on the log-transformed scale and Extended Data Fig. 3b shows the relationships between incident disease and step counts as a log relative hazard function that is not indexed to the median step count value. These results confirm general relationships between higher daily steps and lower disease risk. Table 2
models the adjusted HR for each condition when moving from the 25th percentile for average daily step counts to the 75th percentile, which gives insight into the distribution of risk across the spectrum of step counts. Participants with step counts at the 75th percentile have 24–52% lower risk of developing diabetes, hypertension, GERD, MDD, obesity and sleep apnea, compared with those who were in 25th percentile.

Fig. 2 | Relation between daily steps over time and incident chronic disease. 
\(a\), Cox models were used to compute HRs as a function of average daily step count. Median step counts of 8,160 (diabetes), 8,290 (essential hypertension), 8,260 (GERD), 8,210 (major depressive disorder), 8,280 (obesity) and 8,220 (sleep apnea) were used as reference. \(b\), Cumulative incidence by year for each outcome as a function of average daily step count. Shaded area represents 95% CI. All the Cox models were adjusted for age, race, sex, CAD, cancer, BMI, systolic blood pressure, education level, smoking and alcohol use.
adjusted for a priori covariates. Results were similar across limited and full a priori models as well as those that accounted for wear time and baseline step counts over the first 3 and 6 months (Table 2, Models 1–5).

We next modeled risk of obesity as a function of baseline BMI, daily step counts and BMI*steps interaction using recorded BMI values rather than diagnostic codes. We included only individuals who never had a recorded BMI > 30 kg m⁻² or a coded diagnosis of obesity at any time before or during the first 6 months of monitoring (N = 1,067). This analysis was designed to address potential concerns regarding incidence estimates confounded by conditions that were prevalent but undiagnosed at baseline. Figure 3 and Supplementary Table 3 show that the risk of obesity decreases substantially at higher step counts, even when the baseline BMI is near the threshold for obesity. For example, when starting at a baseline BMI of 28 kg m⁻², risk of obesity is reduced by 36% (95% CI 20–49%) when step counts increase from the 25th to 75th percentile. This increase in step counts resulted in a 50% reduction in cumulative incidence of obesity at 5 years from 16% (95% CI 11, 20) at the 25th percentile compared with 8% (95% CI, 12) at the 75th percentile.

A trajectory analysis in which steps were plotted at discreet time periods before disease diagnosis showed lower baseline step counts

---

**Table 2 | HRs, 95% CI and P values for 75th step count percentile versus 25th percentile with respect to each continuous Cox model and diagnosis**

| Model/diagnosis | Sample size (N) | Events (n) | 25th percentile (thousands) | 75th percentile (thousands) | HR (75% versus 25%) | 95% CI | P value |
|-----------------|----------------|------------|-----------------------------|-----------------------------|---------------------|-------|---------|
| **Model 1**     |                |            |                             |                             |                     |       |         |
| Diabetes        | 5,124          | 156        | 6.05                        | 10.63                       | 0.44                | 0.28, 0.68 | <0.001  |
| Hypertension    | 4,437          | 482        | 6.18                        | 10.73                       | 0.71                | 0.55, 0.91 | 0.007   |
| GERD            | 4,613          | 432        | 6.14                        | 10.76                       | 0.64                | 0.56, 0.73 | <0.001  |
| MDD             | 4,884          | 467        | 6.09                        | 10.72                       | 0.63                | 0.55, 0.72 | <0.001  |
| Obesity         | 4,774          | 368        | 6.16                        | 10.77                       | 0.52                | 0.43, 0.62 | <0.001  |
| Sleep apnea     | 4,922          | 348        | 6.11                        | 10.70                       | 0.53                | 0.45, 0.63 | <0.001  |
| **Model 2**     |                |            |                             |                             |                     |       |         |
| Diabetes        | 5,124          | 156        | 6.05                        | 10.63                       | 0.68                | 0.56, 0.84 | <0.001  |
| Hypertension    | 4,437          | 482        | 6.18                        | 10.73                       | 0.76                | 0.59, 0.98 | 0.033   |
| GERD            | 4,613          | 432        | 6.14                        | 10.76                       | 0.66                | 0.57, 0.76 | <0.001  |
| MDD             | 4,884          | 467        | 6.09                        | 10.72                       | 0.66                | 0.57, 0.76 | <0.001  |
| Obesity         | 4,774          | 368        | 6.16                        | 10.77                       | 0.59                | 0.43, 0.82 | 0.001   |
| Sleep apnea     | 4,922          | 348        | 6.11                        | 10.70                       | 0.48                | 0.35, 0.65 | <0.001  |
| **Model 3**     |                |            |                             |                             |                     |       |         |
| Diabetes        | 5,124          | 156        | 6.05                        | 10.63                       | 0.67                | 0.54, 0.83 | <0.001  |
| Hypertension    | 4,437          | 482        | 6.18                        | 10.73                       | 0.75                | 0.58, 0.98 | 0.031   |
| GERD            | 4,613          | 432        | 6.14                        | 10.76                       | 0.64                | 0.55, 0.74 | <0.001  |
| MDD             | 4,884          | 467        | 6.09                        | 10.72                       | 0.67                | 0.59, 0.78 | <0.001  |
| Obesity         | 4,774          | 368        | 6.16                        | 10.77                       | 0.59                | 0.42, 0.81 | 0.001   |
| Sleep apnea     | 4,922          | 348        | 6.11                        | 10.70                       | 0.54                | 0.45, 0.64 | <0.001  |
| **Model 4**     |                |            |                             |                             |                     |       |         |
| Diabetes        | 5,124          | 156        | 6.05                        | 10.63                       | 0.77                | 0.69, 1.0  | <0.05   |
| Hypertension    | 4,437          | 482        | 6.18                        | 10.73                       | 0.81                | 0.61, 1.07 | 0.14    |
| GERD            | 4,613          | 432        | 6.14                        | 10.76                       | 0.71                | 0.59, 0.84 | <0.001  |
| MDD             | 4,884          | 467        | 6.09                        | 10.72                       | 0.69                | 0.58, 0.82 | <0.001  |
| Obesity         | 4,774          | 368        | 6.16                        | 10.77                       | 0.56                | 0.40, 0.80 | 0.001   |
| Sleep apnea     | 4,922          | 348        | 6.11                        | 10.70                       | 0.49                | 0.35, 0.68 | <0.001  |
| **Model 5**     |                |            |                             |                             |                     |       |         |
| Diabetes        | 5,124          | 156        | 6.05                        | 10.63                       | 0.78                | 0.59, 1.02 | 0.07    |
| Hypertension    | 4,437          | 482        | 6.18                        | 10.73                       | 0.82                | 0.62, 1.08 | 0.158   |
| GERD            | 4,613          | 432        | 6.14                        | 10.76                       | 0.71                | 0.59, 0.86 | <0.001  |
| MDD             | 4,884          | 467        | 6.09                        | 10.72                       | 0.70                | 0.59, 0.84 | <0.001  |
| Obesity         | 4,774          | 368        | 6.16                        | 10.77                       | 0.56                | 0.40, 0.79 | 0.001   |
| Sleep apnea     | 4,922          | 348        | 6.11                        | 10.70                       | 0.49                | 0.35, 0.68 | <0.001  |

Model 1 included steps (time-varying), age, race and sex. Model 2 = Model 1 plus systolic blood pressure, CAD, cancer, smoking, education, alcohol and body mass index. Model 3 = Model 2 plus Fitbit wear time (time-varying). Model 4 = Model 2 plus baseline step counts (averaged over first 3 months). Model 5 = Model 2 plus baseline step counts (averaged over first 6 months).
and a prediagnosis plateau (particularly for hypertension and depression) among those with incidence disease (Extended Data Fig. 4). Based on the findings of Models 4 and 5 shown in Table 2, accounting for baseline daily steps averaged over the first 3 or 6 months in the separate Cox models, in addition to a priori covariates, did not change the relation between daily steps over time with incident conditions. We performed a falsification analysis to examine the association between step counts and incident diagnoses with no expected relationship to step counts. As expected, we found no association between daily step counts and risk of carpal tunnel syndrome (n/N = 131/5,269) or actinic keratosis (n/N = 167/5,242 incident diagnoses) (Extended Data Fig. 5).

**Daily step counts, intensity and incident chronic disease**

Daily step counts and intensity (defined using a steps per minute threshold that indicates slow walking) were positively correlated (ρ coefficient ranges from 0.48 to 0.87, P < 0.001). We observed a gradient of higher disease risk at the intersections of lower daily step counts and lower bout cadence quartiles compared with higher daily step counts and higher bout cadence quartiles (Extended Data Fig. 6). We saw similar trends when this relation was examined on a continuous basis using a probability density plot (Extended Data Fig. 7). When step intensity was defined using the moderate to vigorous intensity steps per minute threshold, similar findings were observed albeit with lower rates of incident disease (Extended Data Fig. 8). Daily step counts remained significantly associated with each condition (all chunk tests P < 0.05) after accounting for step intensity (Extended Data Fig. 9 and Supplementary Table 4). Specifically, the effect estimates, that is, HR, for step counts for diabetes, obesity, sleep apnea, GERD and MDD ranged from 0.64 to 0.81 (Supplementary Table 4).

Regardless of how step intensity was defined, that is, slow walking or moderate to vigorous activity, it was associated with lower risk of chronic diseases (all chunk tests P < 0.05, Supplementary Table 5 and Supplementary Table 6).
Extended Data Fig. 10. The HR for step intensity for incident diabetes, hypertension, GERD, MDD, obesity and sleep apnea ranged from 0.43 to 0.88 (Supplementary Table 5). Step intensity (defined as slow walking) also remained significantly associated with obesity, sleep apnea, MDD, GERD and hypertension after adjusting for step count (all chunk tests \( P < 0.05 \)). When defined using a moderate to vigorous intensity, bout cadence remained significantly associated with obesity, sleep apnea and GERD (all chunk tests \( P < 0.05 \); Supplementary Table 5).

Discussion

We examined the association between step count volume and intensity across the entire spectrum of human disease using commercial activity monitors linked to an individual's EHR. We identified consistent and statistically significant associations between activity levels and incident diabetes, hypertension, GERD, MDD, obesity and sleep apnea. Taking more steps each day was related to lower risk of developing these chronic diseases. Higher step counts were associated with protection from obesity in a high-risk population (BMI 25–29 kg m\(^{-2}\)). Step count was positively correlated with step intensity, regardless of the bout cadence definition. The relation of step counts with disease risk persisted for diabetes, GERD, MDD and sleep apnea even when adjusting for step intensity. Step intensity was also significantly associated with these outcomes. These data provide new, empiric evidence of activity levels associated with chronic disease risk and suggest that integration of commercial wearables data into the EHR may be valuable to support clinical care.

Our findings are consistent with previous literature describing associations between step counts and adverse events\(^{10,11}\). A systematic review by Hall et al.\(^{10}\) found that taking more steps per day was related to lower risk of all-cause mortality, cardiovascular events and incident diabetes. The National Health and Nutrition Examination Survey study, which quantified steps over a 7-day monitoring period and assessed mortality over an average of 10.1 years, found a 51% lower mortality at 8,000 steps per day compared with 4,000 steps per day\(^{12}\). Similar results were reported from a middle-aged, biracial cohort with 7 days of monitoring and over 10 years of follow-up time\(^{13}\). A prospective cohort study conducted in 3,055 community-dwelling adults aged over 70 years found a similar nonlinear relation between daily steps and risk of developing diabetes, where the risk leveled off at 8,000 steps per day\(^{14}\). It is notable that step count thresholds associated with risk of mortality and cardiometabolic disease in prior studies are similar to step count thresholds associated with a wide variety of previously unreported phenotypes in our study. These results suggest that a single step count target of approximately 8,000–9,000 steps per day may be suitable to reduce risk of many common conditions.

Our study design and analytic approach differed from prior studies in important ways that make our results new and clinically relevant. First, prior studies assessed step counts over a single, short (usually 7 days) monitoring period with activity data between the baseline monitoring period and outcomes assessment, often many years later. Short monitoring periods are prone to an observer effect and may not accurately reflect true short- and long-term activity behavior\(^{15}\). In contrast, our models accounted for changes in steps over the entirety of an individual's monitoring period (median of 4 years) rather than a brief snapshot. Second, prior studies have focused on a narrow set of outcomes (for example, mortality, diabetes and cardiovascular disease) ascertained at a single timepoint remote from the initial monitoring period. Our study used a hypothesis-generating phenome-wide association study approach, examining the association between step counts and the human phenome. In this manner, several new associations emerged including GERD, sleep apnea and MDD, which would likely go unidentified if disease phenotypes were selected a priori. Lastly, our analysis permitted incident disease to emerge at any point during clinical care rather than a prespecified follow-up time as performed in most cohort studies. One may speculate that this approach is more accurate with respect to the timing of incident disease and refines the temporal association between longitudinal activity and incident disease.

The findings of this study should be viewed in the context of several limitations. We were not able to account for daily step variations between different types of Fitbit models\(^{16}\) and seasonal differences\(^{17}\) as well as the occurrence of the COVID-19 pandemic because device data were not available at the time of analyses and data were date-shifted to protect privacy of participants. The characteristics of our study sample may limit the generalizability of our findings to more diverse populations. The majority of our cohort was relatively young, female, white and college-educated, and only included participants who owned Fitbit devices. Further, participants engaged in more steps per day (median 7,731 steps per day) than the average steps per day values reported for adults in the USA aged over 60 years\(^{18}\), suggesting that the analytical cohort in this study was more active. The fact that we were able to detect robust associations between steps and incident disease in this active sample suggests even stronger associations may exist in a more sedentary population. Therefore, further studies are needed including participants who are historically under-represented in biomedical research and those with activity levels that more closely mirror the general community.

Our data do not account for nonstepping activity such as swimming or cycling, such nonstepping movement is better captured via waveform or raw accelerometry and may provide additional insight into the association between physical activity and clinical diagnoses. Further, this study was observational in nature; therefore, causation should not be inferred. We acknowledge the potential for reverse causation in which the existence of a condition leads to taking fewer steps rather than the reverse. We attempted to mitigate this concern by focusing only on incident conditions and excluding any incident disease that emerged in the first 6 months of the monitoring period. Further, there is a potential for unmeasured confounding in our analyses because we were not able to account for an exhaustive list of potential confounders such as job status, environmental factors and differences in the usage patterns between participants over time\(^{19}\). Future studies are needed to investigate the impact of user behavior on health outcomes. Additionally, findings from exploratory logistic regression that did not find an association between steps per day and other outcomes such as cardiovascular diseases should be viewed with caution given that the analytical sample was relatively young, reported fewer outcomes and had limited follow-up. We excluded 15.4–16.0% (varies based on the outcome) of months due to fewer than 15 valid days of data in the Cox models. This missingness seems acceptable in comparison with prior studies which considered data to be valid if activity was captured on at least 3 out of 7 days (that is, up to 57% missing data)\(^{20}\). Lastly, we also acknowledge the limitations of using EHR data for outcomes ascertainment and the potential lack of specificity of diagnostic codes. It is possible that conditions are coded improperly, not coded at all or not recognized in the clinic. Nonetheless, our results reflect use of diagnostic codes in clinical practice across various medical systems, including large regional medical centers and federally qualified health centers.

Despite these limitations, the sources of data for our study are unique and offer an example of the potential clinical value of linking wearables data to the EHR. Published activity studies almost exclusively used research-grade actigraphs to measure steps and/or activity counts. In contrast, our data derive from commercially available devices. Although some fidelity is lost between research-grade and commercial devices, data from the latter are highly generalizable to a large portion of the public who own such devices. Activity data in this study date to the creation of a Fitbit account by the user. Therefore, the risk of an observer effect in this cohort is negligible because much of the activity data was collected before the participant consented to AllOfUs.

These findings may have important clinical and public health implications. We were unable to identify any published studies that investigated the association of physical activity data from a wearable
device to health outcomes, defined using an individual's EHR. Therefore, this study provides important new evidence that integration of these data sources is feasible and may provide valuable and actionable information for clinicians. Clinicians could monitor activity trends and provide evidence-based anticipatory guidance for activity tailored to an individual’s clinical characteristics and risk profile. For example, our data suggest that an individual with a BMI of 28 kg m\(^{-2}\) (can lower their risk of obesity 64% (95% CI 51, 80) by increasing steps from approximately 6,000 steps per day to 11,000 steps per day (Fig. 3). Although validation of these results is important, such data provide a necessary first step toward the development of personalized activity prescriptions. Further, wearables can also be used as an adjunct tool to encourage patients to engage in physical activity by allowing them to set, measure and track goals\(^{9}\). Finally, self-reported physical activity or exercise interventions may have potential beneficial effects to lower the incidence of depression\(^{11}\) and lower the severity of obstructive sleep apnea and associated comorbidities\(^{11}\). Therefore, these results provide support for the need for further research to examine the effect of real-world, unstructured physical activity to prevent or mitigate the effects of such conditions, including some previously unidentified activity-disease associations (for example, GERD).

In summary, using the data from AoURP, higher daily step counts were associated with reduced risk of several common, chronic diseases, including diabetes, hypertension, GERD, MDD, obesity and sleep apnea. This association between step counts over time and incident chronic diseases was consistent even after adjusting for potential covariates, including baseline steps per day and step intensity. Step intensity was also significantly associated with these incident diseases, although the relationships were less consistent than with step counts. These findings provide a new, robust source of evidence in support of the physical activity guidelines to prevent the risk of developing chronic diseases. If validated, these results may offer an evidence-base for refining activity recommendations based on an individual’s risk profile. This study also provides an example of the potential clinical value of linking data from commercially available wearables to the EHR.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgments, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41591-022-02012-w.

References
1. Saint-Maurice, P. F. et al. Association of daily step count and step intensity with mortality among US adults. JAMA 323, 1151–1160 (2020).
2. Lee, I.-M. et al. Association of step volume and intensity with all-cause mortality in older women. JAMA Intern Med. 179, 1105–1112 (2019).
3. Piercy, K. L. et al. The physical activity guidelines for Americans. JAMA 320, 2020–2028 (2018).
4. Tudor-Locke, C. et al. How many steps/day are enough? For older adults and special populations. Int J. Behav. Nutr. Phys. Act. 8, 79 (2011).
5. Paluch, A. E. et al. Steps per day and all-cause mortality in middle-aged adults in the coronary artery risk development in young adults study. JAMA Netw. Open 4, e2124516–e2124516 (2021).
6. Bassett, D. R. Jr., Toth, L. P., LaMunion, S. R. & Croueter, S. E. Step counting: a review of measurement considerations and health-related applications. Sports Med. 47, 1303–1315 (2017).
7. Freimer, N. & Sabatti, C. The Human Phenome Project. Nat. Genet. 34, 15–21 (2003).
8. Investigators AoURP. The ‘All of Us’ research program. N. Engl. J. Med. 381, 668–676 (2019).
9. Pendergrass, S. A. & Crawford, D. C. Using electronic health records to generate phenotypes for research. Curr. Protoc. Hum. Genet. 100, e80–e80 (2019).
10. Hall, K. S. et al. Systematic review of the prospective association of daily step counts with risk of mortality, cardiovascular disease, and dysglycemia. Int J. Behav. Nutr. Phys. Act. 17, 78 (2020).
11. Paluch, A. E. et al. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health 7, e219–e228 (2022).
12. Ballin, M. et al. Daily step count and incident diabetes in community-dwelling 70-year-olds: a prospective cohort study. BMC Public Health 20, 1830 (2020).
13. Clemes, S. A., Matchett, N. & Wane, S. L. Reactivity: an issue for short-term pedometer studies? Br. J. Sports Med. 42, 68–70 (2008).
14. Fuller, D. et al. Reliability and validity of commercially available wearable devices for measuring steps, energy expenditure, and heart rate: systematic review. JMIR Mhealth Uhealth 8, e18694 (2020).
15. Garriga, A., Sempere-Rubio, N., Molina-Prados, M. J. & Faubel, R. Impact of seasonality on physical activity: a systematic review. Int J. Environ. Res Public Health 19, 2 (2021).
16. Tudor-Locke, C. et al. Normative steps/day values for older adults: NHANES 2005-2006. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 68, 1426–1432 (2013).
17. Meyer, J., Wasmann, M., Heuten, W., El Ali, A. & Boll, S. C. Identification and classification of usage patterns in long-term activity tracking. In Proc. 2017 CHI Conference on Human Factors in Computing Systems, 667–678 (Association for Computing Machinery, 2017).
18. Tudor-Locke, C. et al. How many days of pedometer monitoring predict weekly physical activity in adults? Prev. Med. 40, 293–298 (2005).
19. Larsen, R. T. et al. Effectiveness of physical activity monitors in adults: systematic review and meta-analysis. Br. Med. J. 376, e068047 (2022).
20. Schuch, F. B. et al. Physical activity and incident depression: a meta-analysis of prospective cohort studies. Am. J. Psychiatry 175, 631–648 (2018).
21. Mendelson, M. et al. Obstructive sleep apnea syndrome, objectively measured physical activity and exercise training interventions: a systematic review and meta-analysis. Front Neurol. 9, 73 (2018).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2023
Methods

Study participants
Participants aged over 18 years were enrolled after an informed consent process at clinics and regional medical centers that compose the AoURP network. A detailed description of AoURP has been published elsewhere. For this study, we used the AoURP Registered Tier Dataset version 5 (R2021Q3R2 Curated Data Repository) available on the AoURP Researcher Workbench, a secure cloud-based platform. This dataset included information on physical measurements and vital signs collected at enrollment, surveys, EHR and Fitbit data from participants enrolled from May 30, 2018 to April 1, 2021. Our analyses focused on participants who owned a Fitbit and agreed to share their Fitbit and EHR data. We excluded participants who did not wear a Fitbit for at least 6 months. The All of Us Research Program Resource Access Board (RAB) has granted a post-hoc exception to the program’s Data and Statistics Dissemination Policy for reporting exact participant counts of less than 20 in some of the analyses reporting in this study, due to the very low risk to participant privacy and potential for re-identification.

Fitbit data
Participants who provided primary consent to be part of the AoURP and share EHR data had an opportunity to provide their Fitbit data under the Bring Your Own Device program. Participants connected their own Fitbit device account with the AoURP Participant Portal and agreed to share their complete data over all time in their Fitbit account. For example, if a participant began tracking in their Fitbit account in May 2015 (that is, before the launch of AoURP), the AoURP data pull captured all existing Fitbit data in their account, not just recent data. A participant could stop sharing their data at any time. Participants’ data had direct identifiers removed and all datetime fields were subjected to date shifting by a random number between 1 and 365 days in accordance with approved AoURP privacy policies.

Fitbit data were reported as daily (steps per day) and intraday (steps per minute) step counts. We examined step intensity using steps per minute data. Intensity was defined using mean bout cadence, that is, steps per minute, which were calculated by averaging the steps over the time when a participant engages in ≥2 consecutive minutes at ≥60 steps per minute (which suggests that the participant is at least engaged in slow walking) across all valid days. Evidence suggests that 10-hour wear time is sufficient to estimate daily physical activity during waking time. Therefore, a valid day was defined as a participant wearing the Fitbit for at least 10 hours per day and reporting at least 100 steps per day. We acknowledge that Fitbit devices have reduced fidelity compared with research-grade actigraphs; however, in systematic reviews, Fitbits outperform other commercially available devices when correlated with research-grade devices.

Outcomes
The primary outcomes were identified using any incident billing code in EHR. We excluded any new diagnoses coded during the first 6 months of monitoring, assuming that such conditions were likely prevalent but not yet recognized clinically. The EHR data from different participating sites were mapped and harmonized using the Observational Medical Outcomes Partnership common data model. We used the ICD to phecode map developed by Zheng et al. to map the EHR data to create phecodes (Supplementary Tables 1 and 2). We mapped ICD9CM and ICD10CM ‘source’ codes found in the AoURP Curated Data Repository to phecodes, which were used as outcomes.

Statistical analyses
A CONSORT diagram was created to describe how many participants as well as Fitbit data, including percent days, were excluded based on the criteria used to create the analytical dataset. Descriptive statistics for participant’s demographic and clinical characteristics were presented by median and IQR for continuous variables and frequency for categorical variables. Mann–Whitney U and chi-squared tests for continuous and categorical variables, respectively, were used to compare these clinical characteristics for the participants that were excluded versus included in the analytical dataset for this study. We used logistic regression and Cox proportional hazard models to examine associations between step counts and incident disease. We first conducted multiple logistic regression models adjusted for age, sex and race, to examine the association between average steps per day over an individual’s entire monitoring period and all available phecodes. ORs and 95% CIs were reported per 1,000 step count increase. These analyses were exploratory in nature and allowed a data-driven approach to identify the diseases with a statistically significant relation with steps per day in a manner that was unconstrained by prior knowledge. The remainder of our analyses focused on disease associations by logistic regression that met a Bonferroni adjusted significance threshold and have a plausible biological link to physical activity. These conditions were then examined in separate continuous time-dependent Cox proportional hazard models with adjustment for relevant covariates. Participants were censored at their last medical encounter, which was defined as latest measurement, laboratory data, procedure or condition code.

The phecode definitions used to map the diseases that were used as an outcome for Cox model analyses can be found in Supplementary Table 1. Steps per day (averaged monthly) was examined as a repeated measure and time-varying variable to account for fluctuations in activity over an individual’s monitoring period. Only daily steps data before incident diagnoses were used in the Cox models. The time components for Cox models were chosen in terms of months. We also performed similar Cox model analyses restricted to individuals who were at high risk of incident obesity by virtue of a baseline BMI of 25–29.9 kg m². To examine whether the relationship between steps per day with the hazard of incident outcomes was linear or nonlinear, restricted cubic spline functions using 3, 4 and 5 knots of steps was fitted with separate Cox models. The model with lowest Akaike information criterion (AIC) value was chosen to then interpret the relation of steps per day with risk of developing a condition. Months for which participants had fewer than 15 days of observations were excluded from Cox models. We also examined the percent months and days that were excluded based on this additional criterion implemented in the Cox models.

To investigate the strength of association between step counts and risk of developing chronic disease, HRs and 95% CIs were computed by comparing 75th and 25th percentiles of daily step counts. We also conducted a falsification analysis to show that daily step counts did not associate diseases with no plausible relationship with activity; in this case, we tested carpal tunnel syndrome and actinic keratosis. All Cox models were adjusted for a priori covariates: age, sex (male, female), race (Black or African American, white, other), coronary artery disease (CAD), cancer (yes, no), BMI, systolic blood pressure, education level (no college, some college, college degree), all time smoking (<100 cigarettes, ≥100 cigarettes) and alcohol use (alcohol participant, not an alcohol participant). All covariates except BMI, systolic blood pressure, CAD and cancer were assessed at enrollment visit via participant surveys. Baseline BMI and systolic blood pressure was extracted using EHR data. CAD and cancer were ascertained using ICD9CM/ICD10CM or Current Procedure Terminology (CPT4) codes as well as ICD9CM/ICD10CM codes, respectively. These codes to define CAD and cancer are shown in Supplementary Table 1. In addition to accounting for a priori covariates, we ran a separate Cox model accounting for wear time, which was considered to be a time-varying covariate. Specifically, wear time was defined as the number of hours in a day that contained non-zero step counts. We also performed trajectory analyses by examining the average daily step counts over 0–3 months, 3–6 months, 6–12 months and 12–24 months for the participants who developed versus those who did not develop the conditions, which were examined in the Cox models. We then accounted for baseline daily steps averaged over the first 3 and 6 months, in separate
Cox models in addition to a priori covariates, in an attempt to mitigate the potential for reverse causation.

To examine the relation between steps per day and step intensity (bout cadence), the Spearman correlation coefficient was computed. Additionally, we descriptively examined the gradient of disease risk by plotting the intersections of daily step counts and bout cadence quartiles. We also used the probability density plot to examine the association between daily step counts and bout cadence quantiles. The online version contains supplementary information.

Multiple imputation with predictive mean matching was performed to handle missing data. The aregImpute function in the rms package was used to fit all Cox models and to compute HRs. The 'anova' function in the rms package was used to assess whether the predictors were significantly associated with the outcome as well as to evaluate significance of nonlinear effects for steps based on the model with the lowest AIC value. Specifically, we performed a Wald x2 test (or 'chunk test') to jointly assess whether all the terms, including nonlinear terms in the restricted cubic spline are zero. If the test is nonsignificant, it indicates that the variable represented by the spline is not associated with the outcome or it does not have a nonlinear relationship with the outcome. The online version contains supplementary information.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
To ensure privacy of participants, data used for this study are available to approved researchers following registration, completion of ethics training and attestation of a data use agreement through the All of Us Research Workbench platform, which can be accessed via https://workbench.researchallofus.org/login.

Code availability
Code used for this study can be made available to users of the All of Us Research Workbench platform by contacting our study team.

References
22. Marshall, S. J. et al. Translating physical activity recommendations into a pedometer-based step goal: 3000 steps in 30 minutes. Am. J. Prev. Med. 36, 410–415 (2009).
23. Tudor-Locke, C. et al. How fast is fast enough? Walking cadence (steps/min) as a practical estimate of intensity in adults: a narrative review. Br. J. Sports Med. 52, 776 (2018).
24. Troiano, R. P. et al. Physical activity in the United States measured by accelerometer. Med Sci. Sports Exerc. 40, 181 (2008).
25. Brooke, S. M. et al. Concurrent validity of wearable activity trackers under free-living conditions. J. Strength Cond. Res. 31, 1097–1106 (2017).
26. Tedesco, S. et al. Validity evaluation of the Fitbit Charge2 and the Garmin vivosmart HR+ in free-living environments in an older adult cohort. JMIR Mhealth Uhealth 7, e13084 (2019).
27. Klann, J. G., Joss, M. A. H., Embree, K. & Murphy, S. N. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS ONE 14, e0212463 (2019).
28. Ramirez, A. H. et al. The All of Us Research Program: data quality, utility, and diversity. Patterns 3, 100570 (2022).
29. The Observational Medical Outcomes Partnership, OMOP Common Data Model. https://ohdsi.github.io/CommonDataModel/ (2022).
30. Zheng, N. S. et al. PhEMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records. J. Am. Med. Inf. Assoc. 27, 1675–1687 (2020).
31. Therneau, T. A package for survival analysis in R, version 2.38 (2015).
32. Morris, T. P., White, I. R. & Royston, P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med. Res. Methodol. 14, 75 (2014).
33. Harrell, F. E., Jr. rms: regression modeling strategies (R package version 5) (2016).
34. Marrie, R. A., Dawson, N. V. & Garland, A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. J. Clin. Epidemiol. 62, 511–517.e511 (2009).
35. Harrell, F. E. Jr & Dupont, M. C. The hmisc package (R package version 3) (2006).

Acknowledgments
The All of Us Research Program would not be possible without the partnership of its participants. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers (1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026558; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IA: AOD20137, AOD22003, AOD16037, AOD21041), Federally Qualified Health Centers (HHSN 263201600085U), Data and Research Center (5 U2C OD023196), Biobank (1 U24 OD023121), The Participant Center (U24 OD023176), Participant Technology Systems Center (1 U24 OD023163), Communications and Engagement (3 OT2 OD03201; 3 OT2 OD023206 and Community Partners (1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276). E.L.B. is supported by R01 HL146588 and 1 R01 HL158941-01A1.

Author contributions
H.M., J.A. and E.L.B. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. H.M., J.A. and E.L.B. were responsible for concept and design. H.M., J.A., S.H., F.E.H. and E.L.B. acquired, analysed or interpreted data. H.M., J.A. and E.L.B. drafted the manuscript. All authors performed critical revision of the manuscript for important intellectual content. H.M., J.A., S.H., F.E.H. and E.L.B did the statistical analysis. E.L.B. obtained funding. H.M., J.A. and E.L.B. provided administrative, technical or material support. E.L.B. was responsible for supervision.

Competing interests
The authors declare no competing interests. The sponsor, All of Us Research Program, as well as Fitbit, had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-022-02012-w.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41591-022-02012-w.
Correspondence and requests for materials should be addressed to Evan L. Brittain.

Peer review information Nature Medicine thanks Ambarish Pandey, Paddy Dempsey and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Michael Basson, in collaboration with the Nature Medicine team.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Consort diagram showing inclusion/exclusion criteria. The flow diagram graphically depicts the steps that were utilized to derive the analytical sample that met the inclusion and exclusion criteria. EHR, electronic health records.
Extended Data Fig. 2 | Frequency of multiple conditions by number. The bar chart depicts number of participants who reported having multimorbidity among 6 conditions, i.e. diabetes, hypertension, gastroesophageal reflux disease, major depressive disorder, obesity and sleep apnea.
Extended Data Fig. 3 | Relation between daily steps counts and incident risk of chronic diseases. Relation between daily steps counts and incident risk of chronic diseases. **a**: Adjusted Hazard ratio on log-transformed scale as a function of average daily steps for each selected outcome. **b**: Log relative hazard as a function of average steps for each selected outcome. All the models were adjusted for age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Shaded area represents 95% confidence interval.
Extended Data Fig. 4 | Trajectory of average daily step counts (mean and 95% confidence interval) among participants who did (status = True) and did not (status = False) develop each of the conditions, that is, diabetes (Sample Size (N) = 5124), essential hypertension (N = 4437), GERD (N = 4613), major depressive disorders (N = 4884), obesity (N = 4774) and sleep apnea (N = 4922) that were examined in Cox Models. Trajectory of average daily step counts (mean and 95% confidence interval) among participants who did (status = True) and did not (status = False) develop each of the conditions, that is, diabetes (Sample Size (N) = 5124), essential hypertension (N = 4437), GERD (N = 4613), major depressive disorders (N = 4884), obesity (N = 4774) and sleep apnea (N = 4922) that were examined in Cox Models. Indentation (>) represents the break in y-axis.
Extended Data Fig. 5 | Relation between daily step counts and incident risk of actinic keratosis and carpal tunnel syndrome. Relation between daily step counts and incident risk of actinic keratosis and carpal tunnel syndrome. 

a: Adjusted Hazard ratios as a function of average daily step count. All the models were adjusted for age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Reference for steps was the median steps count at 8,064 steps. 

b: Cumulative incidence by year as a function of average daily step count for each selected outcome. Shaded area represents 95% confidence interval.
## Extended Data Fig. 6

See next page for caption.
Extended Data Fig. 6 | Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates is number of cases per 1000 people for each diagnosis as a function of step and bout cadence quartiles. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Step quartile intervals (thous.) are as follows: 1: [549.5,87]; 2: [5.87,73]; 3: [7.73,93]; 4: [9.83,33.6]. Bout cadence quartiles are as follows: 1: [68.1,83.6]; 2: [83.6,88.7]; 3: [88.7,94.3]; 4: [94.3,158].
Extended Data Fig. 7 | Probability density plot examining the relation between step counts and bout cadence (step intensity) on continuous spectrum in participants who developed (represented as TRUE) vs. did not develop the condition (represented as FALSE). Probability density plot examining the relation between step counts and bout cadence (step intensity) on continuous spectrum in participants who developed (represented as TRUE) vs. did not develop the condition (represented as FALSE). Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days.
Extended Data Fig. 8 | See next page for caption.
Extended Data Fig. 8 | Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates (number of events shown in brackets) for each diagnosis as a function of step counts and bout cadence (step intensity) quartiles. Incidence rates is number of cases per 1000 people for each diagnosis as a function of step and bout cadence quartiles. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥100 steps/minute across all the valid days. Step quartile intervals (thous.) are as follows: 1: [549.5,87]; 2: [5,87,7,73]; 3: [7.73,9.83]; 4: [9.83,33.6]. Bout cadence quartiles are as follows: 1: [102,109]; 2: [109,111]; 3: [111,114]; 4: [113,207].
Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | Relation between daily steps counts and incident risk of chronic diseases. Relation between daily steps counts and incident risk of chronic diseases. A: Hazard ratio as a function of average daily steps in thousands for each outcome. B: Cumulative incidence as a function of average daily steps for each selected outcome by year. Results of Cox model with average daily bout cadence (step intensity) as covariate, in addition to other covariates: age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Shaded area represents 95% confidence interval.
Extended Data Fig. 10 | See next page for caption.
Extended Data Fig. 10 | Relation between daily bout cadence (step intensity) and incident risk of chronic diseases. Relation between daily bout cadence (step intensity) and incident risk of chronic diseases. a: Hazard ratio as a function of average daily bout cadence (step intensity) for each outcome. b: Cumulative incidence as a function of average daily bout cadence for each selected outcome by year. Results of Cox model with average daily steps, average daily bout cadence addition to other covariates: age, race, sex, coronary artery disease, cancer, body mass index, systolic blood pressure, education level, smoking, and alcohol use. Bout cadence referred to steps per minute computed by averaging the steps over the time when participant engaged in ≥2 consecutive minutes at ≥60 steps/minute across all the valid days. Shaded area represents 95% confidence interval.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a  Confirmed

☐  ☒ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement

☐  ☐ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

☐  ☐ The statistical test(s) used AND whether they are one- or two-sided

Only common tests should be described solely by name; describe more complex techniques in the Methods section.

☐  ☐ A description of all covariates tested

☐  ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

☐  ☐ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

☐  ☒ For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted

Give P values as exact values whenever suitable.

☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

☒ ☒ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

☒ ☒ Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Participants aged over 18 years old were enrolled after an informed consent process at clinics and regional medical centers that compose the All of Us Research Program network.

Data analysis

To ensure participant’s privacy, data from All of Us Research program can be accessed and analyzed through a secured cloud-based platform - Researcher Workbench. Specifically, we used R programming language within Jupyter notebook to conduct analysis. Code used for this study can be made available to users of the All of Us Research Workbench platform by contacting our study team.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. Github). See the Nature Portfolio guidelines for submitting code & software for further information.
Data

Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data used for this study is available to approved researchers following registration, completion of ethics training, and attestation of a data use agreement through the All of Us Research Workbench platform, which can be accessed via https://workbench.researchallofus.org/login.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender
In this study, we have used sex assigned at birth to define the participant characteristics as well as a covariate in the analytical models.

Population characteristics
Participants had a median age of 56.7 years IQR[41.5, 67.5] and median BMI of 28.1 kg/m² IQR[24.3, 32.9] at baseline. Nearly 73%, 84% and 71% were female, White, and with a college degree, respectively.

Recruitment
Participants aged over 18 years old were enrolled after an informed consent process at clinics and regional medical centers that compose the All of Us Research Program network.

Ethics oversight
The All of Us Research Program uses high-quality security technology to help keep participant data safe. The data that participants give to the All of Us Research Program are personal. To protect this information, the program follows strict security protocols and processes that are regularly reviewed and updated by the Institutional Review Board (IRB) of the All of Us Research Program.

Further, the row-level participant’s data can only be accessed by registered users on the All of Us Researcher Workbench—secured cloud-based platform. Further, all the registered users have successfully completed the mandatory education training on conducting responsible and ethical research with data from All of Us participants.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/hr-reporting-summary-flat.pdf

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description
Observational longitudinal cohort study.

Research sample
6042 participants who possess their own Fitbit and consented to link activity data and electronic health records (EHR) within the All of Us Research Program and 56 months of Fitbit monitoring data.

Sampling strategy
All of Us Research Program is an initiative that is accumulating multiple streams of health-related information (e.g., electronic health records [EHRs], genomics, physical measures, participant surveys and wearables such as Fitbit) in 1,000,000 or more Americans and includes a focus on populations usually under-represented in biomedical research to date.

Data collection
For this study, we used the All of Us Registered Tier Dataset version 5 (R2021C03R Curated Data Repository) available on the All of Us Researcher Workbench, a secure cloud-based platform. This dataset included information on physical measurements and vital signs collected at enrollment, surveys, EHR and Fitbit data from participants enrolled from May 30, 2018 to April 1, 2021. Our analyses focused on participants who owned a Fitbit and agreed to share their Fitbit and EHR data. We excluded participants who did not wear a Fitbit for at least 6 months.

Timing
For this study, data from participants enrolled from May 30, 2018 to April 1, 2021 in All of Us Research Program were used.

Data exclusions
Of the 329,070 All of Us participants available at the time of our analysis, 214,206 participants had consented to share EHR data. Of
Data exclusions

Those sharing EHR data, 6,042 participants linked their own Fitbit device, had valid Fitbit data over at least 6 months of total monitoring and were aged at least 18 years at any time during the monitoring period.

Non-participation

We are using data from All of Us Research Program. As noted in the All of Us Responsible Conduct of Research training, the Researcher Workbench employs a data passport model, through which we are not conducting human subjects research with All of Us data for two reasons: (1) The research will not directly involve participants, however, it only includes their data; and (2) the data available in the Researcher Workbench has been carefully checked and altered to remove identifying information while preserving its scientific utility. Therefore, we do not have access to information around non-participation to the program. However, for our study, of the 329,070 All of Us participants available at the time of our analysis, 323,028 participants were not included in the analyses because they did not consent to share EHR data or had missing/invalid Fitbit data.

Randomization

Observational longitudinal study design was employed to investigate the research question. Therefore, instead of randomization, covariate adjustment method was used. All Cox models were adjusted for age, sex (Male, Female), race (Black or African American, White, other), coronary artery disease [CAD] (yes, no), cancer [yes, no], body mass index (BMI), systolic blood pressure, Education level [no college, some college, college degree], all time smoking (< 100 cigarettes, >= 100 cigarettes), and alcohol use [alcohol participant, not an alcohol participant]. All covariates except BMI, systolic blood pressure, CAD and cancer were assessed at enrolment visit via participant surveys. Baseline BMI and systolic blood pressure was extracted using EHR data. CAD and cancer were ascertained using ICD9CM/ICD10CM or Current Procedural Terminology (CPT4) codes as well as ICD9CM/ICD10CM codes, respectively.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| ✗   | Antibodies            |
| ✗   | Eukaryotic cell lines |
| ✗   | Palaeontology and archaeology |
| ✗   | Animals and other organisms |
| ✗   | Clinical data         |
| ✗   | Dual use research of concern |

### Methods

| n/a | Involved in the study |
|-----|-----------------------|
| ✗   | ChIP-seq              |
| ✗   | Flow cytometry        |
| ✗   | MRI-based neuroimaging |